HMNC Brain Health Raises $50M Series B Led by MEDICE

Why It Matters

The capital infusion moves HMNC closer to late‑stage trials, potentially delivering the first biomarker‑guided depression treatments and reshaping the psychiatric drug market.

Key Takeaways

• $50M Series B led by MEDICE grants EU rights to KET01.
• KET01 showed rapid antidepressant effect with fewer dissociative side effects.
• Phase II missed primary endpoint, delaying Phase III launch.
• Nelivabon targets genetically defined depression subgroups for precision therapy.
• Investor roster now includes football star Toni Kroos, signaling broader appeal.

Pulse Analysis

HMNC Brain Health, a Munich‑based biotech founded a decade ago to overhaul psychiatric treatment, announced the closing of a $50 million Series B financing round in early 2026. Led by German healthcare firm MEDICE, the round also secured European commercialisation rights to HMNC’s oral ketamine formulation, KET01 (branded Ketabon). The infusion of capital is earmarked for Phase III trial preparation and to accelerate the parallel development of Nelivabon, a vasopressin V1b receptor antagonist designed for genetically defined depression cohorts. The deal underscores a growing willingness among traditional pharma and investors to back precision‑medicine approaches in mental health.

KET01’s clinical journey has been a mixed bag. A Phase II study involving 117 treatment‑resistant depression patients demonstrated rapid symptom relief and a markedly lower incidence of dissociative effects compared with conventional ketamine or esketamine, yet it failed to achieve statistical significance on its primary 21‑day endpoint. This shortfall pushed the programme back into a “Phase III readiness” phase, extending the development timeline beyond the original 2022 target. Meanwhile, Nelivabon has posted encouraging Phase IIb data, leveraging biomarkers to identify patients most likely to respond, thereby aligning closely with HMNC’s original precision‑psychiatry vision.

The broader landscape for psychiatric drug development is shifting. After years of retreat by big‑pharma players, renewed interest in novel mechanisms—ketamine derivatives, psychedelics, and biomarker‑guided therapies—has attracted fresh capital and regulatory curiosity. HMNC’s financing, bolstered by high‑profile investors such as football star Toni Kroos and veteran backer Carsten Maschmeyer, reflects this resurgence. If the upcoming Phase III trials validate KET01’s efficacy and safety, or if Nelivabon reaches market approval, HMNC could set a precedent for precision psychiatry, potentially unlocking a new class of targeted antidepressants and reshaping reimbursement models for mental‑health care.

Deal Summary

Munich-based HMNC Brain Health completed the first closing of a $50 million Series B round, led by German healthcare company MEDICE, which also secured European commercialisation rights for HMNC’s ketamine candidate KET01. The funding will support Phase III preparation for KET01 and further development of its second lead programme, Nelivabon.